Entering text into the input field will update the search result below

Novo Nordisk says FDA approves new indication for Ozempic

Jan. 16, 2020 7:11 PM ETNovo Nordisk A/S (NVO)NVOBy: Carl Surran, SA News Editor9 Comments
  • Novo Nordisk (NYSE:NVO) says the Food and Drug Administration approved a new indication for Ozempic (semaglutide) to "reduce the risk of major adverse cardiovascular events such as heart attack, stroke or death in adults with type 2 diabetes and known heart disease."
  • Novo says the FDA decision was based on results from the SUSTAIN 6 trial, which examined "the cardiovascular safety of adding Ozempic or placebo to standard of care in adults with type 2 diabetes and established cardiovascular disease."
  • Ozempic already is indicated for use to improve blood sugar in adults with type 2 diabetes mellitus and to reduce the risk of major cardiovascular events in adults with type 2 diabetes mellitus with known heart disease.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.